

Information on the Total Number of Voting Rights and Shares (Denominator)

Liège, Belgium – 31 March, 2026 – 7:30 CET – Regulated Information – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Hyloris Pharmaceuticals SA (“**Hyloris**”) (Euronext Brussels: HYL), the specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, publishes a voluntary Denominator update following an issue of new subscription rights:

- Share capital: EUR 140,001.87
- Total number of securities carrying voting rights: 28,000,374 (all ordinary shares)
- Total number of voting rights (= denominator): 28,000,374 (all relating to ordinary shares)
- Number of rights to subscribe for securities carrying voting rights not yet issued: 955,480 subscription rights, entitling their holders to subscribe for a total number of 955,480 securities carrying voting rights (all ordinary shares)*

* 250,000 new subscription rights were issued before notary on March 30, 2026 (after the publication of the previous denominator press release of 2 February 2026).

Important comment: A change in the number of subscription rights does not in itself require a press release. A press release is only required when there is a change in the number of shares (or voting rights) or the share capital, in which case an update must be provided on the number of subscription rights (and convertible bonds). **Hyloris hereby announces that it will no longer issue such voluntary press releases in future.**

About Hyloris Pharmaceuticals

Hyloris is the specialty biopharma company focused on innovating, reinventing, and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals and payors. The Company’s development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)(2) pathway in the U.S or equivalent regulatory frameworks in other regions which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten the development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio of 28 products, including 25 value-added medicines of which two products are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high barrier generic products approved in the U.S. and one high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).

For more information, please visit www.hyloris.com and follow us on [LinkedIn](#).



Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO

legal representative of Impact WITH Empathy BV

Ann.dejaeger@hyloris.com

32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO

legal representative of SVR Management BV

Stijn.vanrompay@hyloris.com

32 (0)4 346 02 07

Christophe Maréchal, CFO

Représentant légal de CMM&C SRL

Christophe.marechal@hyloris.com

+32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

